Medullary carcinoma of the thyroid is cancer of the thyroid gland that starts in cells that release a hormone called calcitonin. These cells are called "C" cells. The thyroid gland is located inside the front of your lower neck.
Thyroid - medullary carcinoma; Cancer - thyroid (medullary carcinoma); MTC; Thyroid nodule - medullary
The cause of medullary carcinoma of the thyroid (MTC) is unknown. MTC is very rare. It can occur in children and adults.
Unlike other types of thyroid cancer, MTC is less likely to be caused by radiation therapy to the neck given to treat other cancers during childhood.
There are two forms of MTC:
You have an increased risk for this type of cancer if you have:
Other types of thyroid cancer include:
MTC often begins as a small lump (nodule) in the thyroid gland. There also may be lymph node swelling in the neck. As a result, symptoms may include:
Treatment involves surgery to remove the thyroid gland and surrounding lymph nodes. Because this is an uncommon tumor, surgery should be performed by a surgeon who is familiar with this type of cancer and experienced with the operation required.
Further treatment will depend on your calcitonin levels. A rise in calcitonin levels again may indicate new growth of the cancer.
Near relatives of persons diagnosed with hereditary forms of MTC are at increased risk of this cancer and should discuss with their providers.
Steven Waguespack is an Endocrinologist and a Pediatrics expert in Houston, Texas. Waguespack has been practicing medicine for over 29 years and is rated as an Elite expert by MediFind in the treatment of Medullary Thyroid Carcinoma. He is also highly rated in 27 other conditions, according to our data. His top areas of expertise are Medullary Thyroid Carcinoma, Thyroid Cancer, Papillary Thyroid Cancer, Tissue Biopsy, and Hormone Replacement Therapy (HRT). Waguespack is currently accepting new patients.
Ian Ganly is an Otolaryngologist in New York, New York. Ganly has been practicing medicine for over 34 years and is rated as an Elite expert by MediFind in the treatment of Medullary Thyroid Carcinoma. He is also highly rated in 35 other conditions, according to our data. His top areas of expertise are Thyroid Cancer, Tongue Cancer, Papillary Thyroid Cancer, Laryngectomy, and Tissue Biopsy. Ganly is currently accepting new patients.
Mark Zafereo is an Otolaryngologist in Houston, Texas. Zafereo has been practicing medicine for over 18 years and is rated as an Elite expert by MediFind in the treatment of Medullary Thyroid Carcinoma. He is also highly rated in 20 other conditions, according to our data. His top areas of expertise are Anaplastic Thyroid Cancer, Thyroid Cancer, Papillary Thyroid Cancer, Medullary Thyroid Carcinoma, and Laryngectomy. Zafereo is currently accepting new patients.
You can ease the stress of illness by joining a cancer support group. Sharing with others who have common experiences and problems can help you not feel alone.
Most people with MTC live at least 5 years after diagnosis, depending upon the stage of the cancer. The 10-year survival rate is 65%.
Complications may include:
Contact your provider if you have symptoms of MTC.
Prevention may not be possible. But, being aware of your risk factors, especially your family history, may allow for early diagnosis and treatment. For people who have a very strong family history of MTC, the option to remove the thyroid gland may be recommended. You should carefully discuss this option with a doctor who is very familiar with the disease.
Summary: A study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment (cabozantinib or vandetanib) for participants with RET (rearranged during transfection)-mutant MTC who have not previously received a SOC MultiKinase Inhibitor (MKI) therapy. Participants will be randomized in a 1:1 ratio into one of two treatment arms: Arm A (pralsetinib) or Arm B (investigator's choice of eith...
Background: - Medullary thyroid cancer (MTC) is a rare cancer of the thyroid gland. In children and adults, it is often part of a condition called Multiple Endocrine Neoplasia 2 (MEN2). MEN2 is usually caused by a genetic mutation, and it can cause a number of problems in addition to MTC. These problems include adrenal gland tumors, hormone changes, and problems with the bones and other organs. Not much is kn...
Published Date: January 25, 2022
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Insoo S, Sosa JA. Thyroid. In: Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL, eds. Sabiston Textbook of Surgery. 21st ed. Philadelphia, PA: Elsevier; 2022:chap 37.
Jonklass J, Cooper DS. Thyroid. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 213.
National Cancer Institute website. Thyroid cancer treatment (adult) (PDQ) - health professional version. www.cancer.gov/types/thyroid/hp/thyroid-treatment-pdq. Updated February 18, 2022. Accessed June 14, 2022.
Viola D, Elisei R. Management of medullary thyroid cancer. Endocrinol Metab Clin North Am. 2019;48(1):285-301. PMID: 30717909 pubmed.ncbi.nlm.nih.gov/30717909/.
Wells SA Jr, Asa SL, Dralle H. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. PMID: 25810047 pubmed.ncbi.nlm.nih.gov/25810047/.